A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemonaïve non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Y-M, Perng, R-P, Shih, J-F, Lee, Y-C, Lee, C-S, Tsai, C-M, Whang-Peng, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409551/
https://www.ncbi.nlm.nih.gov/pubmed/14735177
http://dx.doi.org/10.1038/sj.bjc.6601526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409551/
https://www.ncbi.nlm.nih.gov/pubmed/14735177
http://dx.doi.org/10.1038/sj.bjc.6601526

Ejemplares similares